Spots Global Cancer Trial Database for Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Official Title: Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL
Study ID: NCT01516567
Study Description
Brief Summary: Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.
Detailed Description:
Keywords
Eligibility
Minimum Age: 6 Months
Eligible Ages: CHILD
Sex: ALL
Healthy Volunteers: No
Locations
University Hospitals Leuven, Leuven, , Belgium
Children Oncology Group Operations centres, Monrovia, , Canada
Gustave Roussy, Villejuif, , France
2nd Dept. of Pediatrics Semmelweis Univ., Budapest, , Hungary
Associazione Italiana di Ematologia ed Oncologia Pediatrica, Padova, , Italy
Emma Children's Hospital, Amsterdam, , Netherlands
Rectorat of Medical University, Wroclaw, , Poland
Sociedad Española de Hematología y Oncología Pediátricas, Valencia, , Spain
University of Birmingham, Birmingham, , United Kingdom
Contact Details
Name: Catherine PATTE, MD
Affiliation: Institut Gustave Roussy, Villejuif, FRANCE
Role: STUDY_CHAIR
Name: Thomas GROSS, MD
Affiliation: Children's Oncology Group, USA
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
